Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Current Deferred Revenue (2022 - 2024)

Historic Current Deferred Revenue for Century Therapeutics (IPSC) over the last 3 years, with Q4 2024 value amounting to $109.2 million.

  • Century Therapeutics' Current Deferred Revenue rose 239688.93% to $109.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $109.2 million, marking a year-over-year increase of 239688.93%. This contributed to the annual value of $109.2 million for FY2024, which is 239688.93% up from last year.
  • Century Therapeutics' Current Deferred Revenue amounted to $109.2 million in Q4 2024, which was up 239688.93% from $3.6 million recorded in Q3 2024.
  • Over the past 5 years, Century Therapeutics' Current Deferred Revenue peaked at $109.2 million during Q4 2024, and registered a low of $3.6 million during Q3 2024.
  • Over the past 3 years, Century Therapeutics' median Current Deferred Revenue value was $6.4 million (recorded in 2022), while the average stood at $14.4 million.
  • As far as peak fluctuations go, Century Therapeutics' Current Deferred Revenue plummeted by 4887.07% in 2023, and later skyrocketed by 239688.93% in 2024.
  • Over the past 3 years, Century Therapeutics' Current Deferred Revenue (Quarter) stood at $7.2 million in 2022, then crashed by 38.89% to $4.4 million in 2023, then surged by 2396.89% to $109.2 million in 2024.
  • Its Current Deferred Revenue was $109.2 million in Q4 2024, compared to $3.6 million in Q3 2024 and $4.4 million in Q2 2024.